newsfilter
← Latest News
Business Wire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • On Monday, October 13, 2025, Tvardi shares fell over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial for TTI-101.
  • The trial aimed to assess safety, pharmacokinetics, & exploratory outcomes for idiopathic pulmonary fibrosis but failed to meet its goals regarding lung function changes.
  • Preliminary results showed similar baseline characteristics across arms, with placebo-treated patients having lower percent predicted Forced Vital Capacity (FVC) than those treated with TTI-101.
  • Investors who suffered significant losses are encouraged to contact partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • The law firm has offices in New York, Pennsylvania, California, & Georgia & has recovered hundreds of millions of dollars for investors since 1995.
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.